AstraZeneca Total Liabilities and Share Holders Equity 2010-2024 | AZN

AstraZeneca total liabilities and share holders equity from 2010 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
  • AstraZeneca total liabilities and share holders equity for the quarter ending June 30, 2024 was $104.340B, a 8.08% increase year-over-year.
  • AstraZeneca total liabilities and share holders equity for 2023 was $101.119B, a 4.8% increase from 2022.
  • AstraZeneca total liabilities and share holders equity for 2022 was $96.483B, a 8.43% decline from 2021.
  • AstraZeneca total liabilities and share holders equity for 2021 was $105.363B, a 57.9% increase from 2020.
AstraZeneca Annual Total Liabilities and Share Holders Equity
(Millions of US $)
2023 $101,119
2022 $96,483
2021 $105,363
2020 $66,729
2019 $61,377
2018 $60,651
2017 $63,354
2016 $62,526
2015 $60,056
2014 $58,595
2013 $55,899
2012 $53,534
2011 $52,830
2010 $56,127
2009 $54,920
AstraZeneca Quarterly Total Liabilities and Share Holders Equity
(Millions of US $)
2024-06-30 $104,340
2024-03-31 $102,293
2023-12-31 $101,119
2023-09-30 $96,086
2023-06-30 $96,543
2023-03-31 $96,687
2022-12-31 $96,483
2022-09-30 $94,185
2022-06-30 $96,579
2022-03-31 $100,273
2021-12-31 $105,363
2021-09-30 $107,221
2021-06-30 $73,641
2021-03-31 $64,926
2020-12-31 $66,729
2020-09-30 $64,112
2020-06-30 $59,929
2020-03-31 $57,211
2019-12-31 $61,377
2019-09-30 $58,906
2019-06-30 $61,889
2019-03-31 $61,055
2018-12-31 $60,651
2018-09-30 $61,443
2018-06-30 $61,344
2018-03-31 $63,281
2017-12-31 $63,354
2017-09-30 $64,587
2017-06-30 $65,119
2017-03-31 $60,959
2016-12-31 $62,526
2016-09-30 $63,222
2016-06-30 $64,419
2016-03-31 $64,323
2015-12-31 $60,056
2015-09-30 $54,118
2015-06-30 $55,169
2015-03-31 $53,701
2014-12-31 $58,595
2014-09-30 $56,164
2014-06-30 $58,539
2014-03-31 $59,390
2013-12-31 $55,899
2013-09-30 $54,121
2013-06-30 $53,987
2013-03-31 $52,329
2012-12-31 $53,534
2012-09-30 $52,448
2012-06-30 $51,390
2012-03-31 $50,763
2011-12-31 $52,830
2011-09-30 $52,576
2011-06-30 $53,406
2011-03-31 $54,534
2010-12-31 $56,127
2010-09-30 $56,390
2010-06-30 $54,647
2010-03-31 $54,075
2009-12-31 $54,920
2009-09-30 $51,899
2009-06-30 $50,200
2009-03-31 $46,515
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $199.957B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51